MEDVidi Review
GLP-1 weight-loss telehealth · Independently scored 6.6/10
Best for: a licensed provider to prescribe brand glp-1 they fill with insurance
MEDVidi scores highest on the strength of its clinical program — drug options and dosing support.
What the plan covers
Medication
Billed separately
Provider visits
Included
Shipping
Billed separately
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide), plus Saxenda, Qsymia and phentermine. It runs on a per-visit consult model rather than a bundled subscription: an initial appointment is 195 dollars and a follow-up is 159 dollars, and prescriptions go to the patient's chosen pharmacy, so medication cost is separate. MEDVidi operates in 33 states. This is a distinct brand from MEDVi (medvi.com).
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Vetted alternatives to MEDVidi
DudeMeds
Best for: men seeking no-fee compounded or brand-name GLP-1 injections
Editorial score · methodology
Oak
Best for: compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-brand compounded GLP-1 with hormone and performance programs
Editorial score · methodology
MEDVidi at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide, Zepbound, Wegovy
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Consult
- FDA status
- No FDA warning letter on record
How we scored MEDVidi
Each dimension is scored algorithmically from MEDVidi’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
6.2/10MEDVidi does not post a standard monthly cash price up front, so cost transparency is limited — confirm the ongoing rate before you commit. Pricing is flat across doses, so there is no escalation markup as you titrate up.
Effectiveness25%
7.6/10MEDVidi offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
6.9/10Online intake and platform experience — consult included in the price; 6 platform features disclosed.
Trust & Safety15%
6.8/10Core details confirmed by our editors; no FDA warning letters on file.
Accessibility10%
5.6/10MEDVidi's exact state footprint isn't published — confirm coverage in your state before signing up.
Support10%
5.4/10MEDVidi provides standard clinician follow-up; no extended coaching or community program is disclosed.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this MEDVidi review
Last checked August 2026- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
What we checked
- FDA warning-letter register
- No letter on file for this provider
GLP-1 medications MEDVidi offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
What we like
- Licensed providers can prescribe brand-name Zepbound and Wegovy
- Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
- Prescriptions sent to the patient's pharmacy of choice, so insurance can be used
Watch-outs
- Consult-fee model: medication is not included and its cost is separate
- No medication pricing is published
- State list is shown as a map rather than enumerated
Is MEDVidi worth it?
The short version of what MEDVidi offers is a licensed provider to prescribe brand glp-1 they fill with insurance. It's a fairly plain, no-frills entry in the glp-1 providers category, without a lot of extra add-ons layered on top of the medication itself.
How much MEDVidi actually costs
MEDVidi doesn't post a standard monthly price publicly, which makes it the exception rather than the rule in this category. Start a consultation to get an exact quote, and confirm the ongoing rate — not just any first-month offer — before you commit to anything.
Medications: what MEDVidi prescribes
MEDVidi prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two most-studied weight-loss molecules on the market today.
Who MEDVidi is best for — and who should skip it
A good fit if you…
- want a straightforward telehealth GLP-1 program without a lot of extra features to evaluate.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen instead of a compounded formulation — that's not what this provider fills.
- need to bill insurance, since like most of this market it's cash-pay with no claims filed on your behalf.
Trust, safety, and medical oversight
We found no FDA warning letter on file for it, though a clean record isn't the same as an endorsement — read the rest of this review for the full picture. We explain in detail how we weigh medical oversight, safety, and pricing transparency in our scoring methodology, which is worth reading before you sign up with any provider.
Bottom line
MEDVidi could be worth a look, but it doesn't publish a standard price up front — get a quote and confirm the ongoing rate before deciding, and compare it against the alternatives below. If you're comparison-shopping, Collective is one of the closest alternatives we track — worth a look before deciding.
The Bottom Line
MEDVidi scores highest on the strength of its clinical program — drug options and dosing support.
Ready to start with MEDVidi?
See current pricing and start your free consultation.
MEDVidi might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this MEDVidi review:
Sources & methodology — as of October 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
See MEDVidi's current pricing
Start your free consultation to check eligibility and today's price.